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Abstract: The brain is a highly metabolically active organ producing large amounts of reactive oxygen species (ROS). 
These ROS are kept in check by an elaborate network of antioxidants. Although ROS are necessary for signaling and  
synaptic plasticity, their uncontrolled levels cause oxidation of essential macromolecules such as membrane lipids, nucleic 
acids, enzymes and cytoskeletal proteins. Indeed, overproduction of ROS and/or failure of the antioxidant network lead  
to neuronal oxidative stress, a condition associated with not only aging but also Alzheimer’s disease (AD). However,  
the specific source of excessive ROS production has not yet been identified. On one hand, amyloid beta (A) has been  
extensively shown to act as an oxidant molecule. On the other hand, oxidative stress has been shown to precede and  
exacerbate A pathology. This review will address the involvement of oxidative stress in the context of neuronal as well 
as vascular dysfunction associated with AD. 
Keywords:  Alzheimer’s disease, amyloid , oxidative stress, reactive oxygen species, blood flow, learning, memory,   
axonal transport. 
INTRODUCTION 
  Alzheimer’s disease (AD) is a progressive neurodegen-
erative disorder affecting 5.3 million individuals in the 
United States alone [1]. It is characterized by severe cogni-
tive dysfunction and drastic personality changes, mirrored 
molecularly by two main pathological hallmarks: 1) in-
creased levels of toxic amyloid  (A) oligomers, which 
eventually accumulate into extracellular senile plaques, and 
2) hyperphosphorylation of the microtubule-associated pro-
tein tau, which eventually clumps into intracellular neurofi-
brillary tangles [2,3]. Although the pathological hallmarks of 
AD are well defined, the characteristics of disease progres-
sion vary greatly among individuals, making it difficult to 
pinpoint specific clinical determinants for the onset and pro-
gression of AD. The identification of several gene mutations 
that predispose the carrier for AD has been instrumental in 
furthering the current understanding of AD pathology. These 
include the amyloid precursor protein (APP) and presenilin 
(PS) genes [4]. Mutations in these genes invariably lead to 
increased levels of the A protein, the main component of 
senile plaques, placing this protein at the center of the most 
popular theory for AD: the A cascade theory also called 
amyloid hypothesis of AD [2,5]. This theory has influenced 
and guided AD research for over a decade, and it is still re-
garded by many as the main hypothesis for pursuing scien-
tific and clinical investigation of the disease. In the past few 
years, however, many studies emerged and opened way for 
criticism of the amyloid hypothesis. For example, questions 
arose when research findings from the amyloid hypothesis 
did not advance the therapeutic management of the disease, 
nor did it shed light on the selective affliction of certain   
individuals. Perhaps, one of them major flaws of the theory  
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is that it does not explain why many aged, but cognitively 
normal individuals, exhibit abundant A deposition with no 
signs of clinical AD. Additionally, cases of sporadic AD, 
with no underlying genetic increase in A, constitute the 
larger portion of cases. Non-genetic AD has been proposed 
to be a vascular disorder, whose underlying cause is   
impaired cerebral blood flow [reviewed in 6]. Although A 
also contributes to non-genetic cases of AD, it is becoming 
increasingly clear that multiple factors come into play to 
precipitate the occurrence of AD. 
  One such factor, supported by studies from both animal 
models and human patients, is oxidative stress, which is im-
plicated in AD-related vascular as well as neuronal dysfunc-
tion [7-11]. These studies include extensive reports demon-
strating the oxidizing potential of A, implying oxidative 
stress involvement downstream of A [12-25]. However, 
despite the overwhelming evidence for the pro-oxidant role 
of A, several studies have demonstrated free radical in-
volvement in AD prior to A-associated cognitive deficits 
and neuronal pathology and also have implicated ROS in-
crease in modulation of A levels and oligomerization status 
[26-31]. 
  Although it is clear that oxidative stress contributes to 
AD, the exact time of this contribution remains ambiguous. 
This review will first describe oxidative damage, present 
evidence for its involvement in the etiology of AD, and then 
will discuss this involvement in the context of neurodegen-
eration, cognitive deficits, tau hyperphosphorylation and 
vascular dysfunction associated with AD. 
OXIDATIVE STRESS 
  Oxidative stress occurs when free radical production ex-
ceeds the antioxidant defense mechanisms, leading to oxida-
tive damage of various cellular components, such as pro-
teins, lipids and nucleic acids [10,32-40]. The majority of 
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piratory chain, where an inefficient electron transfer to oxy-
gen during oxidative phosphorylation and ATP production 
results in local overproduction of reactive oxygen species 
(ROS), most notably superoxide anions from complexes I 
and III of the mitochondrial respiratory chain [41,42]. ROS 
are necessary for normal cellular functions such as signaling 
and synaptic plasticity. ROS have been implicated as modu-
lators of memory formation [43-45] and long-term potentia-
tion [46-48], a form of synaptic plasticity widely studied as  
a cellular substrate for learning and memory [49,50]. They 
have also been shown to regulate synaptic plasticity-related 
molecules, including calcium/calmodulin kinase II (CaMKII) 
[51], the extracellular signal-regulated kinase (ERK) [52-54], 
and cyclic adenosine monophosphate (cAMP) response ele-
ment binding protein (CREB) in the hippocampus [53, 55]. 
Under physiological conditions, ROS levels are maintained 
at low manageable levels by a cassette of antioxidant mole-
cules such as glutathione and ascorbate, and antioxidant en-
zymes such as catalase, superoxide dismutase, glutathione 
reductase and glutathione peroxidase [56,57]. When ROS 
levels exceed the antioxidant capabilities of the cell, oxida-
tive damage will ensue. ROS are typically categorized as 
neurotoxic molecules and exert their detrimental effects via 
oxidation of essential molecules such as enzymes and cy-
toskeletal proteins [35, 58, 59]. 
  High ROS levels are associated with the aging process, 
where there is ROS overproduction in conjunction with a 
reduction in the cellular antioxidant defense [60-62]. The 
brain is particularly vulnerable to oxidative stress because of 
its high oxygen consumption. Although a relatively small 
organ by mass, the brain consumes about 20% of the body’s 
total oxygen due to its metabolic activity and high need for 
ATP [63]. Neurons are naturally rich in mitochondria to 
meet this high energy demand, and therefore produce higher 
levels of ROS [64,65]. The brain is also rich in fatty acids 
which are prone to oxidative damage [65] and has relatively 
poor antioxidant systems [64], resulting in limited ability to 
cope with the large amount of ROS produced. Consistent 
with the idea of the brain being particularly vulnerable to 
oxidative stress, excessive ROS have been associated with 
decreased performance in cognitive tasks, both in physio-
logical aging and pathological conditions that promote   
oxidative stress, such as AD [27,43-45,66-69].  
  ROS undoubtedly are very important physiological me-
diators of plasticity and signaling, but can become detrimen-
tal to neuronal function when they accumulate excessively in 
the brain. The following section will present evidence for the 
involvement of oxidative stress in the events leading to AD. 
ALZHEIMER’S DISEASE AND OXIDATIVE STRESS 
  In 1986, Martins and colleagues described increased ac-
tivity of the glucose-6-phosphate dehydrogenase and 6-
phosphogluconate dehydrogenase, which are enzymes of the 
hexose monophosphate pathway, in brains of AD patients 
compared to age-matched controls [70]. This increase was 
proposed to be a direct response to the elevated brain perox-
ide metabolism [70], and represented one of the first reports 
of the involvement of oxidative stress in AD pathology. 
Since then, a multitude of reports directly demonstrated   
extensive oxidative damage in association with AD. This 
includes lipid peroxidation [32-34, 36], protein carbonylation 
[10, 37] and oxidative damage to nucleic acids [35, 38, 40, 
71]. Lipid peroxidation causes damage at several levels: 1) it 
generates various reactive aldehydes, which can incorporate 
into proteins to generate carbonyl derivatives [72], 2) 4-
hydroxynonenal (4-HNE), a product of lipid peroxidation 
can alter the phospholipid asymmetry of the membrane lipid 
bilayer, leading to apoptotic neuronal loss in both mild cog-
nitive impairment and AD [73] and 3) products of lipid per-
oxidation can react with mitochondrial enzymes, disrupting 
mitochondrial energetics, increasing free radical release and 
therefore leading to further oxidative stress [74]. The addi-
tion of carbonyl groups (such as aldehydes or ketones) on 
proteins occurs as a result of several oxidative reactions. 
Carbonylated proteins tend to be more hydrophobic and re-
sistant to proteolysis, allowing accumulation of non-fully 
functional proteins. Oxidative damage to nucleic acids, espe-
cially in neurons, inevitably leads to neurodegeneration, 
which is a characteristic of AD. 
  Oxidative damage in AD may also be a direct result of 
oxidative toxicity by A. Indeed, soluble A species have 
been linked to an increased hydrogen peroxide (H2O2) and 
decreased cytochrome C oxidase activity in the Tg2576 
mouse model of AD [14]. A has also been shown to induce 
the formation of mitochondrial ROS via  activation of 
NMDA receptors in mature hippocampal neurons [75]. A 
has also been shown to enter the mitochondria and cause a 
signaling amplification that inactivates SOD-2 and generates 
additional free radicals [12]. Additionally, APP the precursor 
for A, has been shown to be targeted to neuronal mitochon-
dria, with the possibility of contributing to mitochondrial 
dysfunction and impaired energy metabolism under specific 
pathological conditions [13]. The production of free radicals 
by A can also occur following disruption of metal ion ho-
meostasis, including copper (Cu) and iron (Fe) [15,16]; For 
example, A can bind Cu ions via a histidine bridge [17,18], 
with the possibility of reducing Cu(II) to Cu(I). This reduc-
tion reaction releases H2O2 as a byproduct [19], which 
causes oxidative damage to cellular components and also 
reacts with A/Cu complexes to produce the more toxic hy-
droxyl radical [20].  
  Markers of oxidative stress have also been tightly linked 
to A: both nucleic and mitochondrial DNA damage have 
been localized to senile plaques in the brains of AD patients 
[21]; lipid peroxidation products and damaged membranes 
are associated with plaques as well [22,23], and advanced 
glycation end products are present in both tangles and 
plaques [24,25]. Further involvement of oxidative damage in 
AD is evident from studies demonstrating elevated levels of 
antioxidant enzymes in the hippocampus and amygdala of 
AD patients. The mitochondrial superoxide dismutase 
(SOD2) has been particularly shown to be elevated in the 
hippocampus of AD patients [9,76,77]. Incidentally, the in-
crease in SOD2 levels was least pronounced in area CA1 
[76] which is required for memory formation and suffers the 
most neuronal degeneration during AD [78]. Elevated anti-
oxidant enzyme levels indicates a possible compensatory 
upregulation of antioxidant defenses in response to increased 
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  Importantly, oxidative damage occurring during AD, 
possibly induced by A, may further exacerbate A toxicity 
by modulating the amyloid pathway. For example, hydroxyl 
radicals, in addition to causing cellular oxidative damage to 
proteins, lipids and nucleic acids, can also react with A 
causing the formation of di-tyrosine cross-linking between 
A peptides which leads to enhanced oligomerization and 
aggregation [79,80]. Additionally, Siegel and colleagues 
demonstrated that elevated levels of 4-HNE, a product of 
lipid peroxidation, promote A aggregation and fibril forma-
tion via covalent modifications of the protein [81]. In line 
with these findings, work from our lab recently demonstrated 
that genetically reducing mitochondrial superoxide by SOD2 
overexpression in the Tg2576 mouse model of AD shifts the 
A pool towards a less amyloidogenic composition and 
therefore plaque deposition is reduced [27]. Specifically, we 
showed that, while the total levels of A are unchanged, the 
ratio of A42 to A40 and also plaque formation are signifi-
cantly reduced following superoxide reduction. These find-
ings suggest that free radicals of mitochondrial origin inter-
fere with the process of A aggregation and subsequent ac-
cumulation into plaques [27]. Along the same lines, Feng 
and colleagues demonstrated that resveratrol, the antioxidant 
found in wine polyphenols, interferes with A fibril forma-
tion but does not affect the levels of A oligomers [30]. -
secretase, the enzyme responsible for A formation from its 
precursor APP, has been shown to be upregulated following 
hypoxia and ischemic injury, suggesting that oxidative stress 
and hypoxia inducible factor 1 (HIF1) play a critical role 
in inducing A overproduction [82]. Conversely, transgenic 
Tg2576 AD model mice with reduced SOD2 activity, and 
therefore increased oxidative stress, have been shown to ex-
hibit increased amyloid burden [83,84] and increased tau 
hyperphosphorylation [84,85], both of which are major hall-
marks of AD. Interestingly, the increased tau hyperphos-
phorylation could be resolved by treatment with the catalytic 
antioxidant EUK189, indicating that tau pathology is a direct 
cause of increased oxidative stress [84].  
  While it remains a matter of debate whether oxidative 
stress or A pathology occurs first in the series of events 
leading to AD, it is clear that both pathologies coexist and 
potentiate each other during AD; A is a pro-oxidant and 
oxidative stress increases A levels. Whether occurring first 
or subsequent to A increases, oxidative stress is associated 
with the early stages of AD and is omnipresent during the 
course of the disease. It contributes to both AD-associated 
neuronal and vascular pathologies that will be discussed in 
the following sections. 
NEURONAL OXIDATIVE STRESS IN ALZHEIMER’S 
DISEASE 
Neurodegeneration 
  A large number of studies offered ample evidence for the 
neurotoxic effect of A, however the mechanisms of neuro-
toxicity remain elusive [reviewed in 86]. Part of the A-
induced neurotoxicity has been attributed to the oxidant po-
tential of A, and will be the focus of this section. For exam-
ple, treatment of rat forebrain neurons with A led to neu-
ronal death that was exacerbated by the presence of Cu and 
improved with catalase treatment [20,87]. This is consistent 
with the previously mentioned notion that A/Cu complexes 
produce H2O2 [19], indicating that at least part of A toxicity 
is due to its ROS generating potential. A similar effect was 
observed in flies, where A toxicity has been shown to be 
mediated by hydroxyl radicals produced by the Fenton reac-
tion, as manipulations reducing Fe lead to reduced protein 
carbonylation and prolonged survival of flies, despite the 
presence of A [88]. These studies provide strong support 
for AD therapies based on metal chelation to alleviate the 
pro-oxidant environment created by metals in the brain. This 
approach, however, was substantially slowed down by the 
host of side effects of metal chelators and the obstacles en-
countered in their tissue-specific targeting, a problem that 
may find its solution in recent nanotechnology advances 
[89]. Interestingly, Cu has been shown to bind APP and 
stimulate its processing via the non-amyloidogenic pathway, 
leading to A reduction [90]. Although this may potentially 
be useful in AD therapeutics, the binding of Cu to APP pro-
duces high levels of ROS; the authors suggest that Cu ago-
nists lacking the ROS producing capability should be ex-
plored for AD therapy [90]. A more recent study demon-
strates that increased levels of APP promote Cu efflux from 
the cells causing reduced Cu bioavailability and adverse ef-
fects on the Cu/Zn superoxide dismutase (SOD1) [91]. This 
effect is mitigated by dietary intake of Cu which stabilizes 
SOD1 and reduces A formation [91]. Although this study 
does not address oxidative stress, the positive effect on 
SOD1 could possibly have implications on oxidative stress 
simply by improving the antioxidant capability of the cell. 
Additionally, the use of EUK-8, a synthetic catalytic free 
radical scavenger, proved effective against A toxicity in 
cell culture [92] and supplementation with antioxidants such 
as blueberries [93], the flavonoids Silibinin [94] and luteolin 
[95], the polyphenol resveratrol [30,96], Ginkgo biloba ex-
tract [31,97,98], epicatechin [99], zeatin [100] and melatonin 
[101] reduced markers of A-induced oxidative toxicity, 
such as cell death and accumulation of lipid peroxidation, 
both  in vitro and in vivo. The antioxidant melatonin pre-
vented the A-induced cell death in organotypic hippocam-
pal slices, and significantly reduced the phosphorylation of 
tau, glial activation and the A-induced increase of inflam-
matory cytokines, suggesting that A-induced cell damage is 
partly mediated via oxidative stress-induced neuroinflamma-
tion and tau hyperphosphorylation [102]. Glial cells play an 
important role in the A-induced neurotoxicity leading to 
dementia. For example, García-Matas demonstrated that A 
activates astrocytes both in vitro and in vivo and that this 
activation is potentiated by the presence of the pro-oxidant 
agents buthionine sulfoximine, a glutathione synthesis in-
hibitor, and FeSO4, which liberates redox active iron. These 
agents potentiated A-induced free radical damage, inflam-
matory damage and apoptosis, suggesting that oxidative 
stress plays an integral role in A-induced neurotoxicity 
[103]. This idea is further supported by studies investigating 
the effects of a novel dietary antioxidant derived from the 
purple sweet potato anthocyanins (PSPA) on A toxicity in 
vitro. The results of such studies showed that PSPA treat-
ment lead to a reduction in intracellular ROS concomitant 
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lar apoptosis, suggesting that A-induced toxicity occurs, at 
least in part, via  a pathway involving oxidative damage 
[104]. 
  A number of studies report the beneficial effects of die-
tary supplementation with the antioxidant Docosahexaenoic 
acid (DHA) on cognition and synaptic integrity in various 
AD models [reviewed in 105]. Hashimoto and colleagues 
very recently demonstrated that DHA improves the A-
induced DNA damage and axodendritic loss and reduces the 
levels of A-induced lipid peroxidation. The authors suggest 
that this might be the basis of the DHA-induced amelioration 
of A-induced neurodegeneration and related cognitive defi-
cits [29]. Similar to DHA, the antioxidant phytochemical 
cyanidin 3-O-glucopyranoside (Cy-3G) has also been found 
to reduce cell death elicited by A oligomers in neuronal cell 
cultures [26]. It also prevented the early events leading to 
death, such as A oligomer binding to the plasma membrane 
and disrupting its integrity [26]. These findings further sup-
port the early involvement of oxidative stress in A-induced 
neurotoxicity. Interestingly, the latter two studies [26,29], 
along with the Ginkgo biloba study [31], also showed that 
the various antioxidants used inhibited A aggregation and 
fibrillation, lending support to the notion of oxidative stress 
involvement in the oligomerization of A into its more toxic 
form [27,30]. 
Learning and Memory  
  Subjects with established AD-related cognitive dysfunc-
tion have been shown to have an imbalance in free radical 
production and antioxidant quenching mechanisms [9, 10, 
106], further implicating oxidative stress in AD-related neu-
ronal dysfunction. As mentioned above, SOD2 deficiency 
has been shown to exacerbate the AD pathology in mice, as 
evidenced by increased plaque deposition and worsening of 
cognitive abilities [83]. It has also been shown to accelerate 
the onset of a number of behavioral deficits in the hAPP 
mouse model of AD [107]. Conversely, we and others have 
shown that overexpression of SOD2 in AD mouse models 
overexpressing mutant APP (Tg2576 and Tg19959) reduces 
oxidative stress and prevents memory deficits, as measured 
by a fear conditioning paradigm and the Morris water maze 
[27, 28]. These data are in agreement with several studies 
demonstrating the involvement of mitochondrial free radi-
cals, through SOD-2 deficiency, in increasing AD-related 
cognitive dysfunction and correlating reduced mitochondrial 
ROS with improved learning and memory function [83, 84, 
107, 108]. Recently, Serrano et al., showed that A-induced 
ERK phosphorylation in organotypic hippocampal cultures 
was mediated by redox signaling through NADPH oxidase, 
suggesting similar mechanisms occur during AD [109]. Be-
cause ERK plays a critical role in long term potentiation 
(LTP) [110,111], which is the cellular substrate for learning 
and memory [112], this study indirectly implicated ROS 
produced by NADPH oxidase in the learning and memory 
dysfunction associated with AD. Further confirmation of the 
involvement of oxidative stress in AD-related cognitive defi-
cits came from studies analyzing frontal cortex fractions 
from AD patients, which revealed strong correlations be-
tween the levels of synaptic lipid peroxidation, protein oxi-
dation and nitration with the subjects’ cognitive status [113]. 
The established involvement of oxidative stress in AD-
related cognitive dysfunction prompted increased interest in 
developing antioxidant therapies for the prevention/treatment 
of cognitive decline during AD. Successful animal studies 
demonstrated that dietary supplementation with antioxidant 
molecules or vitamins, including melatonin [101], blueberry 
extract [114], Ginkgo biloba [115], flavonoids [94,95], caro-
tenoids [100], polyphenols [116], ascorbate [117,118], toco-
pherol [119] and various combinations of antioxidants [120-
124], can decrease oxidative stress and improve memory 
function, as measured by various spatial and associative 
memory paradigms. However, the counterpart of such stud-
ies in humans yielded conflicting results: While observa-
tional epidemiological studies are consistent with the hy-
pothesis that there is an inverse relationship between anti-
oxidant intake and AD risk [125-128], randomized clinical 
trials do not unanimously support this hypothesis [129-139]. 
Although this may seem discouraging in terms of antioxidant 
therapeutics for AD, one should not overlook some impor-
tant factors that may have affected the results of such trials. 
For instance, all of the negative trials have in common the 
lack of information about 1) circulating therapeutic levels of 
the antioxidant used and 2) whether the antioxidant therapy 
led to reduced levels of free radicals and/or reduced levels of 
markers of oxidative stress in vivo. This information is im-
portant to measure the success outcome of the studies and 
the lack thereof makes those studies at best inconclusive. 
Failure of antioxidant therapy in clinical trials may also be 
due to multiple factors including reduced bioavailability, 
insufficient length of treatment and/or poor specificity of 
these treatment regimens, suggesting that an antioxidant 
therapeutic approach for AD may benefit both from specific 
targeting and increased antioxidant potency. For example, 
multiple studies have demonstrated a specific involvement of 
mitochondrial ROS in AD pathology [27,28,83,84,107], and 
therefore a specific mitochondrial antioxidant would perhaps 
show more efficacy than a general antioxidant. A set of syn-
thetic plastoquinone derivatives recently were shown to spe-
cifically target the mitochondria and act as potent antioxi-
dants at nanomolar concentrations [140,141]. These re-
chargeable mitochondrial antioxidants (termed SKQs) have 
been shown to be effective in terms of decelerating senes-
cence and treating age-related diseases in rodents [140-146]. 
Although, these agents can become pro-oxidants at higher 
concentrations [140,141], they still show promise as potent 
specific antioxidants and therefore, their therapeutic potential 
should be investigated for AD. 
Tau Hyperphosphorylation and Axonal Transport   
Deficits 
  One important function of neurons that is severely af-
fected during AD is axonal transport [147]. Functionality of 
neurons in the brain is dependent on the cellular machinery 
that controls anterograde and retrograde transport of a vari-
ety of molecules along axons. This machinery primarily in-
volves the microtubule network of the cell, proteins of the 
dynein and kinesin superfamilies, and several microtubule 
associated proteins, including tau. The involvement of ab-
normal tau metabolism in the pathology of AD has been ex-
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ing protein that needs to be partially phosphorylated to func-
tion properly. However, when it becomes hyperphosphory-
lated, not only does it lose its ability to bind microtubules, 
but it also sequesters normal tau and other microtubule-
associated proteins. This leads to the destabilization of mi-
crotubules and results in axonal transport deficits [reviewed 
in 149]. During AD, tau is abnormally hyperphosphorylated 
[3,148] and therefore it is thought to contribute to the AD-
related axonal transport deficits [149]. A and oxidative 
stress have also been suggested to contribute to the axonal 
pathology observed in AD [150]. Tau pathology has been 
shown to occur downstream of A with tau proposed to act 
as an effector of A toxicity, suggesting that A possibly 
induces axonal transport deficits via tau hyperphosphoryla-
tion [151-153]. Furthermore, oxidative stress has amply been 
shown to lead to increased tau hyperphosphorylation, and 
therefore it could also possibly contribute to axonal transport 
deficits via a tau mediated mechanism. For example, Melov 
and associates have shown that increased mitochondrial oxi-
dative stress in AD mice via a reduction of the antioxidant 
enzyme SOD2, leads to exacerbation of the AD phenotype, 
most notably increased tau hyperphosphorylation at the ser-
ine 396 epitope [84]. Recent reports confirm this earlier 
study and demonstrate that chronic oxidative stress leads to 
increased phosphorylation of tau at epitopes 399/404 known 
to occur during tangle formation in AD [85], and that tau 
pathology and mitochondrial dysfunction exert a synergistic 
effect during AD and may be responsible for AD-related 
axonal transport dysfunction [154]. These studies suggest 
that mitochondrial oxidative stress contributes to tau pathol-
ogy and could subsequently contribute to axonal transport 
pathology characteristic of AD. In support of such possibil-
ity, recent data from our laboratory specifically demonstrated 
rescue of AD-related increased tau phosphorylation and re-
duced axonal transport by overexpression of the mitochon-
drial antioxidant enzyme SOD2 [155].  
  Interestingly, a recent study described a novel role for the 
tyrosine kinase Abl related gene (ARG) in phosphorylating 
tau at tyrosine 394 [156]. Although historically most of the 
tau phosphorylation sites have been characterized as serines 
and threonines, recent studies report the possibility of tau 
phosphorylation at tyrosine residues [157]. This particular 
study demonstrates that ARG can phosphorylate tau at tyro-
sine 394 and confirms the occurrence of phospho-tau-394 in 
AD-related tangles [156]. Given the reported role of ARG in 
oxidative stress and neural development [158], this study 
strengthens the notion that oxidative stress is directly related 
to tau hyperphosphorylation. 
VASCULAR OXIDATIVE STRESS IN ALZHEIMER’S 
DISEASE 
  There is clearly a prominent role for free radicals in me-
diating the effects of A on neuronal function [27]. A, 
however, not only accumulates in neuronal parenchyma, but 
can also deposit on blood vessel walls in a process referred 
to as cerebral amyloid angiopathy (CAA) [159,160]. CAA 
has been documented extensively in AD, with a wealth of 
evidence linking AD with vascular dysfunction. This evi-
dence includes existence of cerebrovascular disease in the 
AD brain, blood brain barrier dysfunction, and several com-
mon predisposing cerebrovascular risk factors, such as 
stroke, heart disease, hypertension and atherosclerosis [6, 
161-163]. Clearance of A  via  perivascular channels is 
thought to be impaired during AD, leading to amyloid depo-
sition in blood vessel walls and consequently disruption in 
vasomotor functions [164-166]. Similar to its effect on neu-
rons, A is also cytotoxic to endothelial cells as well as 
smooth muscle cells, leading to enhanced predisposition for 
cerebral hemorrhages [167,168]. 
  The vascular endothelium, which regulates the passage of 
macromolecules from the circulating blood into tissues, is a 
major target for oxidative stress and hence plays an impor-
tant role in transducing the effect of ROS to vascular disease 
[169,170]. One of the main enzymes of the vascular endothe-
lium is the endothelial nitric oxide synthase (eNOS), which 
catalyzes the production of nitric oxide (NO) from L-
arginine [171]. NO is a signaling molecule that mediates a 
wide range of effects in different tissues, but most impor-
tantly promotes vascular smooth muscle relaxation and 
hence regulates vascular tone and blood flow [172-174]. 
Therefore, reduced bioavailability of NO can have serious 
consequences on vascular function. On the other hand, in-
creased production of NO can also be detrimental, especially 
in the presence of high levels of free radicals such as super-
oxide anions. Superoxide reacts with NO much faster than it 
dismutates [175]. This reaction not only reduces NO 
bioavailability, but also produces peroxinitrite which is a 
potent free radical, capable of nitrating tyrosine residues to 
form nitrotyrosine. In addition, peroxinitrite can be proto-
nated to form peroxinitrous acid, which is a source of hy-
droxyl radicals, the most potent of the oxygen radicals, with 
no known detoxifying mechanism for it [176,177]. Evidence 
on increased nitrotyrosine is well described in astrocytes, 
neurons as well as blood vessels of AD brains, both in hu-
mans and mouse models of AD [11,178,179], indicating a 
probable involvement of NO dysregulation in the etiology of 
the disease. Additionally, eNOS levels are increased in 
brains of AD patients and colocalize with nitrotyrosine 
[179]. Interestingly, the metabolism of tetrahydrobiopterin 
(BH4), one of the major cofactors of eNOS, is dysregulated 
during AD [180,181]. Combined with high levels of super-
oxide and its derived oxidants, this condition favors the pro-
duction of NOS-derived superoxide instead of NO [182,183]. 
This uncoupling effect is mediated primarily by Akt-
dependent phosphorylation of eNOS at serine 1177 [184, 
185], which alters the kinetics of electron transfer within the 
enzyme, leading to increased production of superoxide, par-
ticularly at low levels of calcium [186]. Although consistent 
evidence suggests increased NO production during AD, 
plasma from AD patients actually shows reduced bioavail-
ability of NO. The combination of increased NO production 
with increased nitrotyrosine immunoreactivity and reduced 
bioavailability of NO during AD suggests that ROS play a 
critical role in vascular deficits associated with AD. Specifi-
cally, increased free radicals exert a NO scavenging effect, 
which leads to two deleterious consequences: 1) production 
of peroxinitrite and ensuing potentiated oxidative stress and 
2) reduced bioavilability of NO and ensuing hypoperfusion. 
  Similar to pharmacologic studies demonstrating the in-
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function, several groups confirmed oxidative stress involve-
ment in the vascular dysfunction associated with AD. For 
instance, the flavonoid luteolin has been shown to confer 
substantial antioxidant protection to the neurovascular unit 
and subsequently protect from A-induced cognitive dys-
function [95]. Similarly, in vivo treatments with the antioxi-
dants N-acetyl-L-cysteine (NAC) and tempol and the perox-
isome proliferator-activated receptor  agonist pioglitazone 
in AD mice, rescued the cerebrovascular dysfunction and 
selected markers of AD neuropathology, including cerebral 
oxidative stress and glial activation [187].  
  Studies with transgenic mouse models support the notion 
of oxidative stress involvement in vascular function: using 
mutant mice with reduced expression of SOD2, Wenzel and 
colleagues demonstrated an increased oxidative stress with 
disrupted vascular function in these animals in relation to 
cardiac disease [188]. Iadecola and colleagues used an 
NADPH oxidase mutant mouse and showed that free radicals 
derived from the Nox2 subunit of the enzyme mediate 
neurovascular dysregulation in the aging mouse brain,   
further confirming the possibility of oxidative stress in-
volvement in AD-related vascular deficits and dementia 
[189]. In support of these results, we recently demonstrated 
that overexpression of SOD2 in the Tg2576 AD mice rescues 
cerebral blood flow impairments characteristic of AD via an 
eNOS mediated fashion [155]. Blood flow deficits in this 
particular mouse model have been previously reported [190].  
  Collectively, the above-mentioned studies support the 
involvement of oxidative stress in cerebrovascular dysfunc-
tion associated with AD. The mechanism of such involve-
ment has yet to be clarified. In a relatively recent review, 
Zhu and colleagues propose a nice scheme describing the 
potential origination of AD in vascular dysfunction, whereby 
chronic hypoperfusion induces mitochondrial dysfunction 
leading to oxidative stress, which ultimately leads to im-
paired cognition and neurodegeneration [191]. Although this 
hypothesis is very attractive and well supported by published 
data, it does not shed light on cases of pure vascular dementia 
or cerebral amyloid angiopathy that fail to progress to AD. 
CONCLUDING REMARKS 
  The brain is particularly sensitive to oxidative stress be-
cause of its high metabolic activity coupled to a naturally 
lower antioxidant capability. It is therefore likely that oxida-
tive stress plays a critical role leading to neuronal as well as 
vascular abnormalities in AD. It is also evident that oxidative 
stress is an early event that plays an important role in the 
progression of the disease. Although it is unclear whether 
oxidative stress is initiated by the pathological overproduc-
tion of ROS or the decrease in antioxidant capacity, the real-
ity remains that the AD brain lacks the appropriate levels of 
antioxidants needed to neutralize toxic free radicals. There-
fore increasing the levels of brain antioxidants, either as a 
prophylactic or therapeutic approach, is expected to be bene-
ficial to AD. Lessons from past cross-sectional studies and 
clinical trials highlight the need for including previously 
missing information such as circulating antioxidant availabil-
ity and free radical levels following treatment, and also sug-
gest that AD therapeutics may benefit from the design of 
potent targeted antioxidants. 
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